The two businesses contributed $2.2 billion, or around 7%, to Medtronic’s revenue, according to data from CNBC. The spinoff, NewCo, was intended to allow for greater investment in the areas of “highest strategic priority” and help execute Medtronic’s leadership strategy in attractive medtech markets.
However, in the wake of the spinoff, Medtronic no longer invests in patient monitoring or respiratory care lines, according to its investments website.
In addition, nothing has happened with NewCo or Medtronic’s former businesses, and the spinoff company does not have a presence online.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.